Back

Fetal protection against bovine viral diarrhea virus types 1 and 2 after vaccination of the dam with the DIVENCE vaccine

Taberner, E.; Gibert, M.; Montbrau, C.; Munoz, I.; Mallorqui, J.; Santo Tomas, H.; Prenafeta, A.; March, R.

2024-04-15 immunology
10.1101/2024.04.12.589196 bioRxiv
Show abstract

The aim of this study was to demonstrate the efficacy of DIVENCE, a vaccine against BVDV types 1 and 2 (BVDV-1 and BVDV-2) transplacental infection, following a booster regimen in heifers. Calves of two-to-three months of age were given two intramuscular doses three weeks apart and a booster vaccine six months later. Efficacy was evaluated by means of a challenge with virulent BVDV-1 or BVDV-2 administered via the intranasal route at 85 days of gestation. Clinical signs, serology, viral shedding, WBC count and viremia were monitored after the challenge. Sixty-six days post-challenge, the fetuses were assessed for BVDV to detect transplacental infection. The results demonstrate a reduction in hyperthermia, leukopenia, viral shedding, and viremia in vaccinated animals post-challenge with BVDV-1 and BVDV-2. Most importantly, DIVENCE administered prior to breeding protected 94% of the fetuses against BVDV transplacental infection overall across both challenge trials (BVDV-1 and BVDV-2).

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.